followed by administration of 250 µg of intravenous corticotropin (Synacthen, Alliance Pharmaceuticals, United Kingdom). After 60 minutes, another blood sample was obtained for serum cortisol level. Laboratory personnel were blinded to the treatment allocation. The results of the corticotropin stimulation test and of tests for interleukin-6 and tumour necrosis factor-α were blinded to both the treating physicians and study investigators.
Randomization was performed by a central pharmacy using consecutive sealed envelopes and based on computer-generated random allocation in blocks to one of two arms in which participants received intravenous bolus injections every six hours of 5 mL of normal saline containing 50 mg of hydrocortisone or normal saline (placebo). The two interventions were indiscernible. Patients as well as medical, nursing and clinical pharmacist staff remained blinded to the allocated therapy throughout the study. The full dose of the study drug was continued until shock resolution, which was defined as blood pressure stability (i.e., mean arterial pressure > 65 mm Hg) without vasopressors for 24 hours. The six-hourly dose was then reduced by 1 mL every two days until discontinuation. If the mean arterial pressure remained above 65 mm Hg for more than 24 hours without vasopressors after complete cessation of the study drug, this was considered an end point for the intervention. However, if hypotension recurred during weaning, the dose was increased to full dosage again. If hypotension recurred after 24 hours of complete cessation of the study drug, the decision to use hydrocortisone or not as open label was left to the discretion of the treating physician.
Management in the ICU and cointerventions
All patients received hemodynamic monitoring and management, laboratory testing, antimicrobial therapy and stress-ulcer prophylaxis using a standardized protocol. Hemodynamic support followed the early goal-directed therapy protocol of Rivers and colleagues. 21 Norepinephrine was the vasopressor of choice, and meropenem was the empiric antibiotic of choice unless indicated otherwise by cultures and clinical setting. All patients received histamine H 2 -receptor antagonists or proton pump inhibitors for stress-ulcer prophylaxis.
Outcomes
The primary outcome was 28-day all-cause mortality. Secondary outcomes included ICU-specific and hospital-specific mortality, mean arterial pressure, vasopressor doses, shock reversal, vasopressor-free days, mechanical ventilation-free days and renal replacement-free days (during the first 28 study days). We documented length of stay in ICU for ICU survivors and length of stay in hospital for hospital survivors. We documented the occurrence of the following potentially intervention-related side effects: severe hyperglycemia (> 10 mmol/L or > 180 mg/dL), shock relapse (i.e., hypotension recurrence during weaning or within seven days of total discontinuation of the study drug), arrhythmia, gastrointestinal bleeding, bacteremia and ventilator-associated pneumonia (as defined by the National Nosocomial Infections Surveillance System).
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Cortisol, corticotropin and cytokine assays Cortisol was measured by an ARCHITECT analyzer (Abbott, Chicago, USA) using a chemiluminescent immunoassay. Corticotropin was measured using the autochemiluminescence system IMMULITE 2000 (Siemens Medical Solutions Diagnostics, New York, USA). Relative adrenal insufficiency was defined as a cortisol increase of less than 250 nmol/L or 9 µg/dL from baseline after corticotropin stimulation. 13 Samples for tumour necrosis factor-α and interleukin-6 were obtained on days one, three and seven, stored at -80ºC and assayed using a solid-phase chemiluminescent enzyme immunoassay (Immunlite, EURO/DPC Ltd., Gwynedd, UK) according to the manufacturer's specifications. The lowest detectable limit for interleukin-6 was 5 pg/mL, and for tumour necrosis factor-α, it was 1.7 pg/mL.
Statistical analysis
Statistical analyses were performed on an intention-to-treat basis. Based on an estimated baseline 28-day mortality of 90% and an estimated absolute risk reduction of 20%, 75 patients were required in each group using a two-sided type I error of 5% and a power of 80%. Stratified analyses were performed for several variables and were tested for interaction. Detailed descriptions of sample size calculation and statistical analyses, as well as study protocol, are available in Appendices 1 and 2 at www .cmaj .ca /cgi /content /full /cmaj .090707 /DC1. A post-hoc futility analysis was carried out to calculate the conditional power of the study under the following three alternative assumptions: first, that the treatment effect size expected in future data would be the same as that in the original study design; second, that it would be the same as the trend in the data thus far; and third, that it would be zero (i.e., that the null hypothesis is true). 23 
CMAJ 2
Excluded n = 65
• Did not meet inclusion criteria n = 58 • Refused or unable to consent within window of randomization n = 7
Completed study n = 36
Completed study n = 39 
Results

Study description
Of 140 patients screened, 75 were enrolled and randomly allocated ( Figure 1 24 Post-hoc futility analyses yielded very low conditional powers of 3.4% for the first assumption described earlier, 0.00% for the second and 0.01% for the third. These results indicate that it is highly unlikely that a significant treatment benefit would be evident even if the trial were completed to the targeted sample size.
Patient characteristics
Baseline characteristics, including use of etomidate, were similar in the two groups (Table 1 ). Cortisol levels were not different at baseline and increased modestly after corticotropin stimulation to similar levels in the two groups. Overall, 76% of patients had a cortisol increase of less than 250 nmol/L (9 µg/dL) from baseline (i.e., were "nonresponders"), with similar proportions in the two groups. (33) 30 (77) 9 (23) 2 (5) 16 (41) 3 (8) 2 (5) 8 ( .2) 16 (44) 19 (53) (28) 2 (6) 13 (36) 6 (17) 5 (14) 30 (83) 6 (17) 8 (22) 15 (42) 4 (11) 8 (22) 9 ( 
ICU and cointerventions
Clinical parameters, including those related to fluid status and ventilatory pressures, and cointerventions, including transfusion requirements, were similar in the two groups (Table 2) .
Mortality
There was no significant difference between the hydrocortisone and placebo groups in 28-day mortality ( (Table 3) . Kaplan-Meier curves for survival at 28 days (Figure 2 ) also showed no significant difference (p = 0.50). Moreover, there was no significant interaction between response to corticotropin and assigned treatment with respect to 28-day mortality (p = 0.39). 
Hemodynamic response
Other outcomes
There was no difference between the two groups in mechanical ventilation-free days, renal replacement therapy-free days, length of stay in ICU or length of stay in hospital (Table 3) . Hydrocortisone was associated with higher rates of severe hyperglycemia and with a significant increase in the risk of gastrointestinal bleeding (RR 3.00, 95% CI 1.08-8.36).
Stratified analyses
With respect to 28-day mortality, there was no significant interaction between the assigned treatment and use of etomidate, duration of shock before randomization, duration of treatment with the study drug, Acute Physiology and Chronic Health Evaluation II score, or achievement of hemodynamic targets.
Cytokine levels
There was progressive reduction in the levels of interleukin-6 and tumour necrosis factor-α in the hydrocortisone and placebo groups. A significant difference in these levels between the hydrocortisone and placebo groups was seen only for tumour necrosis factor-α and only at day seven (15.6 ± 13.6 pg/ml v. 25.9 ± 18.0 pg/mL, p = 0.03).
Interpretation
Relative adrenal insufficiency was very common among patients with cirrhosis presenting with septic shock. Hydrocor- tisone therapy resulted in a significant hemodynamic improvement, especially in nonresponders to corticotropin. Despite these initial favourable hemodynamic effects, hydrocortisone therapy did not reduce mortality and was associated with an increase in shock relapse and gastrointestinal bleeding. Corticosteroid therapy in septic shock has fallen in and out of favour over the last few decades. 25, 26 Annane and colleagues 13 reported a significant reduction in mortality with hydrocortisone therapy among patients with septic shock -a finding that led to the recommendation of hydrocortisone as a standard therapy in the Surviving Sepsis Campaign. 27 Similar results have been reported in other studies [14] [15] [16] and a metaanalysis. 18 However, the results of the study by Annane and colleagues were considered borderline because they were achieved only after statistical adjustment 28 and because crude in-hospital mortality was higher among responders to corticotropin who received hydrocortisone. More recently, the Corticosteroid Therapy of Septic Shock (CORTICUS) study showed that corticosteroids had no effect on 28-day mortality, even among nonresponders. 17 Relative adrenal insufficiency has recently been described in 62%-80% of heterogeneous groups of patients with liver disease. 11, 12, 29, 30 Our study shows a prevalence of relative adrenal insufficiency reaching 76% in a homogenous group of patients with cirrhosis presenting with septic shock. Several potential mechanisms have been postulated, including adrenal exhaustion, 31 inhibition of cortisol synthesis by tumour necrosis factor-α 32 and, less likely, adrenal hemorrhage. 29 Despite this high prevalence of relative adrenal insufficiency, our study showed no survival benefit with hydrocortisone therapy, although hemodynamic parameters improved significantly. There are several potential explanations. First, it has been suggested that the benefit observed by Annane and colleagues but not in the CORTICUS study was related to the shorter randomization window (8 v . 72 hours) . In our study, 80% of patients were enrolled within the first 24 hours after the onset of shock. Furthermore, we found no interaction between the assigned treatment and the duration of shock before randomization with respect to 28-day mortality.
Second, 33% of our patients had received etomidate, which is known to cause adrenal suppression. 33 However, this proportion was not different in the CORTICUS study (26% of patients) or the study by Annane and colleagues (24% of patients). Furthermore, we found no interaction between the assigned treatment and etomidate use with respect to 28-day mortality. 
Hemodynamic response
Change in norepinephrine infusion rate (day 2 -day 1), μg/kg per min, mean (SD) Vasopressor-free days, mean (SD) 6.8 (7.9) 5.6 (8.9) 1.2 (-2.7 to 5.1)* 0.54
Other outcomes
Ventilation-free days, mean (SD) 6.7 (7.7) 8.1 (10.9) -1.4 (-5.8 to 2.9)* 0.51
Renal replacement therapy-free days, mean (SD) 6.7 (7. Third, Annane and colleagues used fludrocortisone, whereas the CORTICUS study did not. However, cirrhosis is characterized by hyperaldosteronism, 34 which is the basis for the use of aldosterone antagonists to treat ascites. 35 Additionally, the absorption of oral medications is unreliable in patients with cirrhosis, and a daily hydrocortisone dose of 200 mg, which was used in these trials, provides adequate mineralocorticoid activity. 17 Fourth, we observed a significant increase in shock relapse after weaning hydrocortisone. This increase was surprising because of the relatively slow eight-day tapering protocol for hydrocortisone initiated 24 hours after hemodynamic stability was achieved. This protocol contrasts with cessation of corticosteroids after seven days by Annane and colleagues and tapering from day 5 to 11 in the CORTICUS study, regardless of hemodynamic status. In the CORTICUS trial, shock relapse was observed in 31% of the hydrocortisone group and 25% of the placebo group. However, since hydrocortisone was tapered in some patients while vasopressors were still required, these numbers may underestimate the hemodynamic deterioration due to steroid tapering. The very high mortality associated with relapse of shock may have mitigated any beneficial effects of hydrocortisone. Why did shock recur after tapering of hydrocortisone? It is possible that relative adrenal insufficiency is inherent in patients with cirrhosis and not a temporary sepsis-related phenomenon, and as such, a longer duration of therapy might be required. Alternatively, hydrocortisone therapy may have further suppressed the pituitaryadrenal axis, and thus tapering precipitated an adrenal crisis.
Fifth, use of low-dose (often called "stress-" or "physiologic-dose") hydrocortisone is not free of adverse effects. We observed a three-fold increase in gastrointestinal bleeding with very high associated mortality, which may have counteracted any potential benefit. Sixth, the low-dose hydrocortisone is not a simple hormone replacement therapy, but rather has clear immunomodulatory effects, as shown by the reduction in pro-inflammatory cytokines, which may alter the body's ability to mount an "appropriate" pro-inflammatory response and host defences. Seventh, relative adrenal insufficiency may be just a marker of illness. If so, hydrocortisone therapy would expose patients only to adverse effects, such as further adrenal suppression, gastrointestinal bleeding and immunosuppression. Finally, patients with cirrhosis and sepsis may constitute a special group that differs in physiology and severity from other ICU patients with sepsis and perhaps in response to hydrocortisone therapy.
The use of a corticotropin stimulation test before hydrocortisone therapy has been debated. A meta-analysis showed beneficial effects of steroid therapy in both responders and nonresponders to corticotropin, 18 and the Surviving Sepsis Campaign considered the test "optional." 27 However, our study does not support hydrocortisone therapy in cirrhosis without a corticotropin stimulation test because of lack of hemodynamic and survival benefits in responders.
The use of free rather than total serum cortisol levels has been suggested for the diagnosis of relative adrenal insufficiency because of dissociation between the levels of the total and the physiologically active free cortisol. 36 However, recent guidelines have not recommended the routine use of free cortisol measurements because of lack of availability and lack of an established normal range in critically ill patients.
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Strengths and limitations Strengths of our study included the randomized double-blind placebo-controlled design, intention-to-treat analysis, homogenous population, inclusion of steroid-naive patients and standardized ICU management. In addition, our protocolized slow tapering of the study drug after achieving predefined parameters of hemodynamic stability was more physiologically appropriate than use of a predefined schedule with abrupt cessation or tapering irrespective of hemodynamic status.
As a limitation, our study was a single-centre trial, which may affect its generalizability. Issues related to the length of our study's randomization window and to the use of etomidate are addressed earlier in the article.
Conclusion
Relative adrenal insufficiency is common in patients with cirrhosis presenting with septic shock. Hydrocortisone therapy was associated with hemodynamic improvement. However, it did not reduce mortality and was associated with an increase in shock relapse and gastrointestinal bleeding. Our results suggest a need for further multicentre randomized controlled trials, possibly using lower doses of hydrocortisone and for a longer duration.
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